Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues

被引:3
|
作者
Avagimyan, Ashot [1 ]
Gvianishvili, Tamuna [2 ]
Gogiashvili, Liana [3 ]
Kakturskiy, Lev [4 ]
Sarrafzadegan, Nizal [5 ]
Aznauryan, Artashes [6 ]
机构
[1] Yerevan State Med Univ, Anat Pathol Dept, Yerevan, Armenia
[2] Ivane Javakhishvili Tbilisi State Univ, Alexandre Natishvili Inst Morphol, Dept Clin & Expt Pathol, Tbilisi, Georgia
[3] Ivane Javakhishvili Tbilisi State Univ, Alexandre Natishvili Inst Morphol, Dept Clin & Expt Pathol, Tbilisi, Georgia
[4] Russian Soc Pathol, FSBI Res Inst Human Morphol, Moscow, Russia
[5] Isfahan Univ Med Sci, Isfahan Cardiovasc Res Inst, Esfahan, Iran
[6] Yerevan State Med Univ, Histol Dept, Yerevan, Armenia
关键词
TRASTUZUMAB-INDUCED CARDIOTOXICITY; SUBCLINICAL HYPOTHYROIDISM; RISK-FACTOR; ANTHRACYCLINE; DOXORUBICIN; DISEASE; PACLITAXEL; PREDICTION; STRESS; HEART;
D O I
10.1016/j.cpcardiol.2021.101051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in the population, as well as the economic burden of the health care system. Currently, CVDs account for more than 17.6 million deaths a year and are projected to exceed 23.6 million by 2030. Unstable atheroma, and its rupture, underlies the pathology of most cardiovascular complications, particularly acute coronary syndrome, mortality from which, compared with other CV events, remains the leading one. Despite numerous efforts by WHO, national health systems, and medical authorities, the incidence and mortality from cardiovascular events remain critically high. Thus, the search for new risk factors for the development of CV pathology looks very relevant. Our working group decided to amalgamate our research data, which reflects the study of modern risk factors from the Armenian, Russian,
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Screening for Prostate Cancer with Prostate-specific Antigen: The Journey Continues
    Albertsen, Peter C.
    EUROPEAN UROLOGY, 2023, 83 (02) : 110 - 111
  • [2] Prostate-specific antigen and screening for prostate cancer
    Han, M
    Gann, PH
    Catalona, WJ
    MEDICAL CLINICS OF NORTH AMERICA, 2004, 88 (02) : 245 - +
  • [3] Prostate-specific antigen for prostate cancer screening
    不详
    BJU INTERNATIONAL, 2023, 131 (03) : 266 - 266
  • [4] Screening for Prostate Cancer with Prostate-specific Antigen
    Al-Monajjed, Rouvier
    Albers, Peter
    Hadaschik, Boris
    EUROPEAN UROLOGY OPEN SCIENCE, 2025, 74 : 71 - 72
  • [5] Update on screening for prostate cancer with prostate-specific antigen
    Schmid, HP
    Riesen, W
    Prikler, L
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 50 (01) : 71 - 78
  • [6] Longitudinal screening for prostate cancer with prostate-specific antigen
    Smith, DS
    Catalona, WJ
    Herschman, JD
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (16): : 1309 - 1315
  • [7] Prostate-specific Antigen Testing and Prostate Cancer Screening
    Djavan, Bob
    Eckersberger, Elisabeth
    Finkelstein, Julia
    Sadri, Helen
    Taneja, Samir S.
    Lepor, Herbert
    PRIMARY CARE, 2010, 37 (03): : 441 - +
  • [8] PROSTATE-SPECIFIC ANTIGEN IN SCREENING FOR PROSTATE-CANCER
    MAYER, FJ
    CRAWFORD, ED
    WESTERN JOURNAL OF MEDICINE, 1994, 160 (02): : 168 - 168
  • [9] The Role of Prostate-Specific Antigen in Prostate Cancer Screening
    Constantin, Traian Vasile
    Madan, Victor Lucian
    Constantin, Maria-Magdalena
    Morariu, Silviu-Horia
    Braticevici, Bogdan
    REVISTA ROMANA DE MEDICINA DE LABORATOR, 2014, 22 (02): : 275 - 281
  • [10] The case for prostate cancer screening with prostate-specific antigen
    Andriole, Gerald
    Djavan, Bob
    Fleshner, Neil
    Schroder, Fritz
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (12) : 737 - 745